Diagenode

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer


Wang W. et al.

Transcription factors play a key role in the development of diverse cancers, and therapeutically targeting them has remained a challenge. In prostate cancer, the gene encoding the transcription factor ERG is recurrently rearranged and plays a critical role in prostate oncogenesis. Here, we identified a series of peptides that interact specifically with the DNA binding domain of ERG. ERG inhibitory peptides (EIPs) and derived peptidomimetics bound ERG with high affinity and specificity, leading to proteolytic degradation of the ERG protein. The EIPs attenuated ERG-mediated transcription, chromatin recruitment, protein-protein interactions, cell invasion and proliferation, and tumor growth. Thus, peptidomimetic targeting of transcription factor fusion products may provide a promising therapeutic strategy for prostate cancer as well as other malignancies.

Tags
HighCell ChIP kit
IPure kit

Share this article

Published
April, 2017

Source

Products used in this publication

  • ChIP kit icon
    C01010063
    HighCell# ChIP kit protein G
  • default alt
    C03010015
    IPure kit v2

イベント

  • CLEPIC 2022
    Szczecin, Poland
    Jun 8-Jun 10, 2022
  • European Socienty of Human Genetics - ESHG 2022
    Wien, Austria
    Jun 11-Jun 14, 2022
  • Lausanne Genomics Days 2022
    Lausanne, Switzerland
    Jun 16-Jun 17, 2022
  • EpiPlant 2022
    Banyuls-Sur-Mer, France
    Jun 22-Jun 24, 2022
 すべてのイベントを見る

ニュース

 すべてのニュースを見る


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics